Renal denervation is an effective and safe catheter-based intervention for significantly reducing elevated blood pressure in patients with uncontrolled primary hypertension.
Does renal denervation reduce elevated blood pressure in patients with uncontrolled primary hypertension?
Renal denervation is highlighted as an effective and safe nonpharmacologic intervention for managing uncontrolled or resistant hypertension.
Uncontrolled hypertension can result from untreated high blood pressure (BP) or the inefficacy of established antihypertensive therapeutic regimens. Renal denervation (RDN) is a nonpharmacologic catheter-based intervention that achieves targeted renal sympathetic nerve ablation to modulate sympathetic activation. RDN is suitable for those with uncontrolled primary hypertension, resistant to therapy or intolerant to drugs, and who have a favorable renal artery anatomy. Long-term data demonstrate RDN's efficacy in significantly reducing elevated BP. RDN procedures have shown a good safety profile, and no significant difference in adverse events has been reported between RDN-treated and control groups in most clinical trials. Thus, RDN offers an effective and safe approach for sustained BP control.
Gopi et al. (Wed,) conducted a review in Uncontrolled hypertension. Renal denervation (RDN) was evaluated on Blood pressure reduction and adverse events. Renal denervation is an effective and safe catheter-based intervention for significantly reducing elevated blood pressure in patients with uncontrolled primary hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: